Also known as: amylin analogue
AbbVie shares declined 2% on March 13, 2026, amid reduced trading volume, while BMO Capital maintained its Outperform rating following Phase 1 obesity drug trial data for ABBV-295.
AbbVie announced positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment, showing clinically meaningful weight loss with favorable tolerability across all dose levels tested.
Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.
Genentech announced positive Phase II results for CT-388, a dual GLP-1/GIP receptor agonist, showing 22.5% placebo-adjusted weight loss at 48 weeks in people with obesity. The treatment was well-tolerated with low discontinuation rates.
Roche announced positive phase II results for obesity drug petrelintide showing 10.7% weight reduction, while the FDA set a December 18 decision date for breast cancer drug giredestrant.
Semaglutide and tirzepatide represent distinct GLP-1-based weight management medications with different mechanisms of action. Clinical trials show varying weight loss outcomes, while new combination therapies undergo head-to-head testing.
